RT Journal Article
SR Electronic
T1 Characteristics and risk factors for SARS-CoV-2 among children in Italy: a cross-sectional study in 20 pediatric centers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.17.21253610
DO 10.1101/2021.03.17.21253610
A1 Marzia Lazzerini
A1 Idanna Sforzi
A1 Sandra Trapani
A1 Paolo Biban
A1 Davide Silvagni
A1 Ilaria Mariani
A1 Giovanna Villa
A1 Jessica Tibaldi
A1 Luca Bertacca
A1 Enrico Felici
A1 Giuseppina Perricone
A1 Roberta Parrino
A1 Claudia Gioè
A1 Sara Lega
A1 Mariasole Conte
A1 Federico Marchetti
A1 Annamaria Magista
A1 Paola Berlese
A1 Stefano Martelossi
A1 Francesca Vaienti
A1 Enrico Valletta
A1 Margherita Mauro
A1 Roberto Dall’Amico
A1 Silvia Fasoli
A1 Antonio Gatto
A1 Antonio Chiaretti
A1 Danica Dragovic
A1 Paola Pascolo
A1 Chiara Pilotto
A1 Ilaria Liguoro
A1 Elisabetta Miorin
A1 Francesca Saretta
A1 Gianluca Trobia
A1 Antonella Di Stefano
A1 Azzurra Orlandi
A1 Fabio Cardinale
A1 Riccardo Lubrano
A1 Alessia Testa
A1 Marco Binotti
A1 Valentina Moressa
A1 Egidio Barbi
A1 Benedetta Armocida
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/03/17/2021.03.17.21253610.abstract
AB Background No study has described factors associated with COVID-19 diagnosis in children.Aim Describe characteristics and risk factors for COVID-19 diagnosis in children tested in 20 pediatric centers across Italy.Methods Cases aged 0-18 years tested for SARS-CoV-2 between February 23 and May 24 2020 were included. Our primary analysis focused on children tested because of COVID-19 suggestive symptoms.Results Among 2494 children tested for SARS-CoV-2, 2148 (86.1%) had symptoms suggestive of COVID-19. Clinical presentation of SARS-CoV-2 included - beside fever (82.4%) and respiratory signs or symptoms (60.4%) – also gastrointestinal (18.2%), neurological (18.9%), cutaneous (3.8%) and other flu-like presentations (17.8%). In multivariate analysis, factors significantly associated with SARS-CoV-2 were: exposure history (adjusted OR 39.83 95%CI 17.52-90.55 p<0.0001), cardiac disease (adjusted OR 3.10 95%CI 1.19-5.02 p<0.0001), fever (adjusted OR 3.05 % 95% CI 1.67-5.58 p=0.0003), and anosmia/ageusia (OR 4.08 95%CI 1.69 −9.84 p=0.002). Among 190 (7.6%) children diagnosed with SARS-CoV-2, only four (2.1%) required respiratory support and two (1.1%) were admitted in ICU, while 100% recovered.Conclusion Recommendations for SARS-CoV-2 testing in children should be updated based on the evidence of broader clinical features. Exposure history, fever, and anosmia/ageusia are strong risk factors for COVID-19 in children, while other symptoms don’t seem helping discriminating in between the SARS-CoV-2 positive and the negative cases. This study confirm that COVID-19 is a mild disease in the general population of children in Italy. Further studies are needed to understand the risk, clinical spectrum and outcomes of COVID-19 in children with specific preexisting conditions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNon external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of the Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy (reference number 01/2020 25.03.2020).Given the purely descriptive and retrospective nature of the study, informed consent was waived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.